South Africa Medical Device Compliance Roadmap 2026 to 2028

1. Key takeaways

The main storyline of South African medical device compliance over the next three years is two parallel timelines: Axis one (certain) — the ISO 13485 five-phase roadmap, with milestones on 1 April 2026 (verification of existing licence holders), 1 June 2027 (changes and product list updates) and 1 April 2028 (all new applications); and Axis two (pending) — the product registration call-up, for which SAHPRA has issued no call-up notice so far, but which is being prepared by the reliance guidance (25 February 2026), the post-market surveillance guidance (9 September 2025) and the feasibility study report (31 March 2026), with the Phase 2 study running until the end of 2027. Complete the certain axis on schedule, and prepare for the pending axis in advance. Companies that treat the two axes as one integrated programme, rather than as separate projects, will avoid the double cost of doing the same work twice under different levels of time pressure.

2. Legal basis

3. Expert insights

Insight one: the three ISO 13485 milestones differ in nature. April 2026 is the stock verification (all existing licence holders, the widest coverage); June 2027 is the incremental threshold (changes and product list updates); April 2028 is the entry threshold (all new applications). They can be read as three steps — clearing the stock, tightening the increments, then closing the entrance — and a company that completes its stock compliance in 2026 will only need to submit at the later milestones in the two years that follow.

Insight two: June 2027 is the milestone most relevant to day-to-day operations. Changes and product list updates are the most frequent actions after licensing. From 1 June 2027, every product list update notification, even a free one, requires the support of an ISO 13485 certificate. Companies should put their system certificate into a state of being ready for submission at any time before that date, otherwise routine operations will stall at the moment the milestone takes effect, in the middle of an ongoing business cycle.

Insight three: the groundwork for the call-up notice is essentially complete. The reliance guidance (the review methodology), the essential principles (the substantive standards), SAHPGL-MD-09 and MD-10 (the dossier structure), SAHPGL-MD-18 (post-market) and the feasibility study report (the process validation) — the methodological layer is nearly complete, and what is missing is an administrative decision. This tells companies that the call-up may be announced with a short lead time, and dossier preparation cannot start too early.

Insight four: the value of the current window lies in bringing forward the long-cycle work. ISO 13485 certification, classification determination, GMDN coding, essential principles argumentation, technical documentation and obtaining foreign approvals — the common features of this work are its long cycles, its capacity to run in parallel, and its independence from the call-up announcement. Complete these now, and after the call-up is published there will be nothing left but submission and deficiency responses.

Insight five: the real risk is waiting. The absence of product registration numbers in South Africa today easily leads companies to conclude that the regime has not landed and that no investment is needed. But the obligations already in force are complete: the establishment licence, ISO 13485, the three vigilance timelines, the annual retention fee, ASOCI, and labelling and instructions for use. The cost of waiting is not zero; it is the accumulation of compliance debt.

4. Practical recommendations

1. 2026: complete the preparations for the ISO 13485 stock verification, and close any establishment licence gaps in the same year.
2. 2027: put the system certificate into a state of ready for submission at any time, covering changes and product list updates.
3. 2028: attach the certificate to every new application, and build certification into the onboarding process for new entities.
4. Advance dossier preparation in parallel: classification, GMDN, essential principles, technical documentation.
5. Establish a call-up notice monitoring mechanism: the Government Gazette and SAHPRA communications.
6. Turn the obligations already in force into an annual compliance calendar: stop depending on the call-up timing.

5. Verification checklist

• □ The 1 April 2026 stock verification milestone is in the annual plan
• □ The 1 June 2027 changes and list update milestone is in the annual plan
• □ The 1 April 2028 new application milestone is in the onboarding process for new entities
• □ The certificate subject, address and CAB on the ISO 13485 certificate have been matched and checked
• □ Dossier preparation (classification, GMDN, essential principles, technical documentation) has started
• □ The reliance evidence package (FDA, CE, TGA, PMDA, Health Canada, ANVISA, WHO PQ) has been assembled
• □ A call-up notice monitoring mechanism is in place
• □ The obligations already in force (licence, ISO 13485, vigilance, retention fee, ASOCI, labelling) are on an annual compliance calendar

Regulatory information verified as of 29 October 2026. The regulations, guidance and effective dates described in this article are limited to the official sources listed in the legal basis section above as published on that date; where official documents have been updated, the most recently published version prevails.

• Local resources in South Africa: GRZAN assists manufacturers from the Chinese mainland and other markets with SAHPRA medical device establishment licence (MDEL) applications and product registration preparation, including authorised representative (AR) scheme design, ISO 13485 certification pathway planning and CAB selection, GMDN coding and classification determination, technical documentation, and the setup of vigilance and adverse event notification mechanisms.
• Service capabilities: product attribute determination and risk classification (Class A, B, C, D), establishment licence applications and renewals, reliance pathway argumentation, technical documentation and essential principles conformity argumentation, labelling and instructions for use localisation in English, and support for post-market vigilance and annual compliance submissions.
• Contact: info@grzanglobal.com; hito.lin@grzan.cn; website www.grzan.cn.